In The Spotlight
Teva Pharmaceutical Industries Ltd and Celltrion Healthcare announce that the companies have entered into an exclusive partnership to commercialize two of Celltrion’s mAb biosimilar candidates in the U.S. and Canada. CT-P10 is a proposed mAb biosimilar to Rituxan® (rituximab).
Daiichi Sankyo Company, Limited has entered into a strategic collaboration with AgonOx, Inc., a privately held biotechnology company, to develop an undisclosed immuno-oncology target.
Boehringer Ingelheim and ViraTherapeutics announced a long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate Vira Therapeutic’s lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other therapies.
ARIAD Pharmaceuticals Inc announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib, in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.
Novartis announced positive topline results from ARISE, the first Phase III study evaluating the efficacy and safety of monthly subcutaneous AMG 334 (erenumab) 70mg in episodic migraine prevention.
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria.
Law enforcement agents, narcotics officers and customs personnel can now quickly and safely detect street drug W-18 and other lethal drugs with the newest library update for the Thermo Scientific TruNarc handheld narcotics analyzer. W-18 is a new designer drug considered to be significantly more potent than morphine and fentanyl.
Janssen Biotech Inc announced that the U.S. FDA has approved STELARA® (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older) who have failed or were intolerant to treatment with immunomodulators or corticosteroids but never failed treatment with a tumor necrosis factor (TNF) blocker, or who failed or were intolerant to treatment with one or more TNF blockers.
WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec company, announced today the opening of a new commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China.
Bosch Packaging Technology, a leading supplier of processing and packaging technology, expands its expertise in the non-aseptic packaging process for pharmaceuticals. Following theintroduction of the Sigpack TTMP topload cartoner for pharmaceutical products,the company now adds two further machines to its portfolio: the Sigpack VPF vertical flat pouch machine and the horizontal flow wrapping machine Sigpack HML.
Taiwan-based papermaking and printing group E Ink Holdings has collaborated with smartphone manufacturer HTC and pharmaceutical packaging solution provider Palladio Group to develop smart packaging label for internet of things (IoT) based healthcare services.
Switzerland-based specialty chemicals group Clariant along with its Healthcare Packaging unit is installing new offset tube printing machines at its production plant in Romorantin, France.